Primo Chemicals Q3 FY26 Consolidated PAT at ₹1.05 Crore
Primo Chemicals reported Q3 FY26 consolidated revenue of ₹14,014.01 lakh and PAT of ₹1.05 crore. For the nine months, consolidated revenue was ₹41,682.87 lakh with PAT of ₹3.83 crore. Standalone Q3 results showed a loss of ₹0.34 crore, while nine-month standalone PAT was ₹5.47 crore. An exceptional item of ₹0.20 lakh was recorded.
The announcement of quarterly financial results is material for investors. While the consolidated profit is positive, the standalone loss and the nature of exceptional items warrant a medium impact assessment.
The results show mixed performance with a consolidated profit but a standalone loss for the quarter. The impact of the new labor codes as an exceptional item adds a neutral factor.
Primo Chemicals Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors approved these results in a meeting held on February 12, 2026.
For the third quarter of fiscal year 2026, consolidated revenue from operations stood at ₹14,014.01 lakh. The consolidated profit after tax attributable to owners was ₹105.47 lakh. For the nine-month period ended December 31, 2025, consolidated revenue was ₹41,682.87 lakh, with a consolidated profit after tax of ₹382.73 lakh.
The company also reported standalone results. For the quarter ended December 31, 2025, standalone revenue from operations was ₹14,014.01 lakh and profit after tax was a loss of ₹34.00 lakh. For the nine-month period, standalone revenue was ₹41,682.87 lakh and profit after tax was ₹546.89 lakh.
An exceptional item of ₹20.06 lakh was recognized due to the statutory impact of new Labour Codes. The company also holds a 49% equity in M/s. FlowTech Chemicals (P) Limited, treated as an Associate.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors. Statutory auditors, S. Tandon & Associates LLP, have issued a limited review report.
What to do with a filing like this
Primo Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Primo Chemicals Limited. Read the original for the full detail.